Kevin church athira
Web31 jan. 2024 · BOTHELL, Wash., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on … Web31 jan. 2024 · Get 7 Days Free Sign In Sign In Topics
Kevin church athira
Did you know?
Web27 mrt. 2024 · Dr has made over 6 trades of the Athira Pharma stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 6,410 units of ATHA stock … Web11 apr. 2024 · Title: Therapeutic Potential of Fosgonimeton, a Small-Molecule Positive Modulator of the Neurotrophic HGF/MET Pathway, in Neurodegenerative Conditions Format: Oral (abstract #3944, presentation #008) Session: S14: General Neurology: Emerging Therapies Presenter: Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma …
Web3 apr. 2024 · Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer Globe Newswire - Jan 31, 2024, 7:00AM Athira Pharma Provides 2024 Pipeline Outlook WebConsultez le profil professionnel de Kevin Church sur LinkedIn. Grâce à LinkedIn, le plus grand réseau professionnel mondial, ... Chief Scientific …
Web31 jan. 2024 · “Kevin is a driving force behind our research at Athira. He is instrumental in leading and directing our efforts to elucidate and validate the promise of the HGF/MET … Web11 apr. 2024 · Presenter: Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma Date/Time: Monday, April 24, at 2:24 p.m. EDT. Title: Fosgonimeton Provides Congruent Improvements on Neurodegeneration Biomarkers, Significantly Correlating with Composite Clinical Score of Cognition and Function in Alzheimer's Disease
WebKevin Church, PhD. Chief Scientific Officer. Kevin entered a career in the life sciences industry in 2006, and has served as the Chief Scientific Officer at Athira since January …
Web23 jan. 2024 · ATHA Athira Pharma, Inc. Kevin Church. Executive VP and Research. Option: 3,152: $1.04: $3,278. 8 Jun 2024 44,133: ↗ Athira Pharma executives and stock … charlotte north carolina job opportunitiesWeb10 apr. 2024 · Presenter: Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma Date/Time: Monday, April 24, at 2:24 p.m. EDT. Title: Fosgonimeton Provides Congruent Improvements on Neurodegeneration Biomarkers, Significantly Correlating with Composite Clinical Score of Cognition and Function in Alzheimer's Disease charlotte north carolina hotelhttp://finance.minyanville.com/minyanville/article/gnwcq-2024-1-31-athira-pharma-announces-promotion-of-kevin-church-phd-to-chief-scientific-officer charlotte north carolina jail inmate searchWeb31 jan. 2024 · “Kevin is a driving force behind our research at Athira. He is instrumental in leading and directing our efforts to elucidate and validate the promise of the HGF/MET … charlotte north carolina humidityWebAthira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND. ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS. charlotte north carolina lotteryWeb1 mrt. 2024 · Dr. Kevin Church Ph.D. is the Exec. VP of Research at Athira Pharma. Last updated: 1 March 2024 at 11:00am EST. Dr. Kevin Church Ph.D. Net Worth charlotte north carolina housesWeb31 jan. 2024 · Dr. Church joined Athira in 2016 and most recently served as Executive Vice President, Research. In his current role, he leads the discovery and preclinical … charlotte north carolina maps